[{"id":"a9f39237-1737-4421-910a-0e37d38262b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083754","created_at":"2023-11-27T22:14:37.322Z","updated_at":"2025-02-25T12:28:25.580Z","phase":"Phase 1","brief_title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","source_id_and_acronym":"NCT05083754","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS","pipe":"","alterations":" ","tags":["PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • carmustine • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-24"},{"id":"b57cb3c0-4fb2-4fdc-add3-151c7aaf3f51","acronym":"SAINT","url":"https://clinicaltrials.gov/study/NCT03138161","created_at":"2024-04-18T20:51:31.500Z","updated_at":"2025-02-25T12:26:41.043Z","phase":"Phase 1/2","brief_title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT03138161 - SAINT","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 07/31/2031","study_completion_date":" 07/31/2031","last_update_posted":"2025-02-24"},{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"e7f1cf47-55e5-465b-a0d2-cff0dfd74a56","acronym":"","url":"https://clinicaltrials.gov/study/NCT03191149","created_at":"2021-01-18T15:44:05.558Z","updated_at":"2025-02-25T12:26:43.341Z","phase":"Phase 2","brief_title":"Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change","source_id_and_acronym":"NCT03191149","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation","tags":["EGFR • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 04/25/2018","start_date":" 04/25/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-24"},{"id":"0f9bc919-4e69-4675-bc62-35e94a94fa58","acronym":"INT22-09-01","url":"https://clinicaltrials.gov/study/NCT05521698","created_at":"2022-08-30T20:56:03.144Z","updated_at":"2025-02-25T13:41:12.118Z","phase":"Phase 1","brief_title":"Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT05521698 - INT22-09-01","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/23/2025","start_date":" 04/23/2025","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2025-02-21"},{"id":"f8d87fba-1ad4-4662-baab-e93772837874","acronym":"Agni-01","url":"https://clinicaltrials.gov/study/NCT06060613","created_at":"2023-09-29T19:11:12.291Z","updated_at":"2025-02-25T14:03:51.690Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","source_id_and_acronym":"NCT06060613 - Agni-01","lead_sponsor":"Obsidian Therapeutics, Inc.","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • OBX-115"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2025-02-19"},{"id":"f5056d6b-3ffd-4e44-961f-b461e0552213","acronym":"A051902","url":"https://clinicaltrials.gov/study/NCT04803201","created_at":"2021-03-17T15:57:46.362Z","updated_at":"2025-02-25T14:15:53.168Z","phase":"Phase 2","brief_title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT04803201 - A051902","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • TNFRSF8 • BCL6 • CXCL13 • ICOS • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • azacitidine • cyclophosphamide • etoposide IV • Copiktra (duvelisib) • vincristine • prednisone • Onureg (azacitidine oral) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-18"},{"id":"64db0bf5-eaaf-49e9-a532-d5f1928d23e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02537418","created_at":"2021-01-18T12:16:25.434Z","updated_at":"2025-02-25T14:06:52.583Z","phase":"Phase 1","brief_title":"Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens","source_id_and_acronym":"NCT02537418","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1 • PD-1 • CTLA4","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 10/16/2015","start_date":" 10/16/2015","primary_txt":" Primary completion: 07/20/2018","primary_completion_date":" 07/20/2018","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-17"},{"id":"efdddd68-b037-4a5e-906c-80c7cd541d58","acronym":"DOVE","url":"https://clinicaltrials.gov/study/NCT06023862","created_at":"2023-09-05T18:12:37.255Z","updated_at":"2025-02-25T13:13:29.101Z","phase":"Phase 2","brief_title":"A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)","source_id_and_acronym":"NCT06023862 - DOVE","lead_sponsor":"Yonsei University","biomarkers":" MSI • PD-1 • WT1","pipe":"","alterations":" ","tags":["MSI • PD-1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • gemcitabine • paclitaxel • doxorubicin hydrochloride • Jemperli (dostarlimab-gxly) • pegylated liposomal doxorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/22/2024","start_date":" 01/22/2024","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-14"},{"id":"f02c2f2b-a093-410f-90e0-01cc532b5f16","acronym":"","url":"https://clinicaltrials.gov/study/NCT04786093","created_at":"2021-03-08T12:53:40.787Z","updated_at":"2025-02-25T15:11:58.304Z","phase":"Phase 2","brief_title":"Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC","source_id_and_acronym":"NCT04786093","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • PD-1 • CTLA4 • NTRK","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion","tags":["PD-L1 • BRAF • ALK • ROS1 • PD-1 • CTLA4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 07/27/2021","start_date":" 07/27/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-13"},{"id":"405369f8-6c34-4eaf-86cd-9b205b8bd8af","acronym":"ETCTN 10183","url":"https://clinicaltrials.gov/study/NCT03854474","created_at":"2021-01-18T19:01:24.885Z","updated_at":"2025-02-25T15:18:02.909Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","source_id_and_acronym":"NCT03854474 - ETCTN 10183","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" EZH2 mutation","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-12"},{"id":"342c2212-312d-4751-97cb-897cdaabd015","acronym":"","url":"https://clinicaltrials.gov/study/NCT06817525","created_at":"2025-02-25T15:38:27.775Z","updated_at":"2025-02-25T15:38:27.775Z","phase":"Phase 2","brief_title":"Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC","source_id_and_acronym":"NCT06817525","lead_sponsor":"Henan Cancer Hospital","biomarkers":" CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • PD-1 • VEGFA • CD4 • FGF • GZMB • TGFB1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • AiRuiKa (camrelizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 11/06/2025","primary_completion_date":" 11/06/2025","study_txt":" Completion: 11/06/2025","study_completion_date":" 11/06/2025","last_update_posted":"2025-02-10"},{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"b3d6c3c2-daaa-494a-aacb-7469cd76f192","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929028","created_at":"2021-06-18T23:52:29.721Z","updated_at":"2025-02-25T16:32:30.069Z","phase":"Phase 2","brief_title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","source_id_and_acronym":"NCT04929028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1 • IFNG • CD4","pipe":" | ","alterations":" PD-1 expression","tags":["PD-L1 • PD-1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 09/15/2029","primary_completion_date":" 09/15/2029","study_txt":" Completion: 09/15/2029","study_completion_date":" 09/15/2029","last_update_posted":"2025-02-07"},{"id":"6fa362b2-89c2-4884-87bd-ac57c53e5ca0","acronym":"E4412","url":"https://clinicaltrials.gov/study/NCT01896999","created_at":"2021-01-29T07:05:03.634Z","updated_at":"2025-02-25T16:36:17.132Z","phase":"Phase 1/2","brief_title":"Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT01896999 - E4412","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1 • CD4 • LGALS1 • ICOS","pipe":" | ","alterations":" TNFRSF8 expression","tags":["PD-1 • CD4 • LGALS1 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Adcetris (brentuximab vedotin) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-06"},{"id":"74305bac-f746-463f-9609-3bbe7cdbf8c8","acronym":"P30CA014089","url":"https://clinicaltrials.gov/study/NCT03049618","created_at":"2021-01-18T15:01:05.004Z","updated_at":"2025-02-25T16:36:52.177Z","phase":"Phase 2","brief_title":"Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475","source_id_and_acronym":"NCT03049618 - P30CA014089","lead_sponsor":"University of Southern California","biomarkers":" PD-L1 • BRAF • ALK • ROS1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRAF • ALK • ROS1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • sEphB4-HSA"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 09/04/2024","primary_completion_date":" 09/04/2024","study_txt":" Completion: 09/04/2024","study_completion_date":" 09/04/2024","last_update_posted":"2025-02-06"},{"id":"f2a83ef8-84cc-449b-9ded-64940f06e812","acronym":"NRG-GY002","url":"https://clinicaltrials.gov/study/NCT02257528","created_at":"2023-12-06T19:15:29.780Z","updated_at":"2025-02-25T16:36:28.321Z","phase":"Phase 2","brief_title":"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer","source_id_and_acronym":"NCT02257528 - NRG-GY002","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • PD-1 • CD4 • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • PD-1 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 05/18/2015","start_date":" 05/18/2015","primary_txt":" Primary completion: 03/05/2019","primary_completion_date":" 03/05/2019","study_txt":" Completion: 03/04/2025","study_completion_date":" 03/04/2025","last_update_posted":"2025-02-06"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"268eae36-cdca-45ae-8506-36b3e8cbd7f6","acronym":"BLAST MRD AML-2","url":"https://clinicaltrials.gov/study/NCT04284787","created_at":"2024-03-22T03:46:14.077Z","updated_at":"2025-02-25T17:00:27.213Z","phase":"Phase 2","brief_title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04284787 - BLAST MRD AML-2","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression • Chr t(15;17)","tags":["PD-L1 • CD8 • PD-1 • IFNG • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Venclexta (venetoclax) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 06/05/2023","primary_completion_date":" 06/05/2023","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"5ba9d628-6d23-4d5d-9027-4c4a55c8330e","acronym":"NCI-2019-08626","url":"https://clinicaltrials.gov/study/NCT04214249","created_at":"2024-01-11T17:17:48.143Z","updated_at":"2025-02-25T17:00:21.915Z","phase":"Phase 2","brief_title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04214249 - NCI-2019-08626","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • CD8 • PD-1 • CD47 • GZMB • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cytarabine • daunorubicin • idarubicin hydrochloride • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-03"},{"id":"7ad02231-e51d-4e77-bde9-f01924b1ddec","acronym":"PELICAN","url":"https://clinicaltrials.gov/study/NCT06232564","created_at":"2024-01-30T19:21:28.994Z","updated_at":"2025-02-25T17:32:47.858Z","phase":"Phase 2","brief_title":"A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs","source_id_and_acronym":"NCT06232564 - PELICAN","lead_sponsor":"Imperial College London","biomarkers":" PD-1 • VEGFA • CD34 • FOXP3","pipe":"","alterations":" ","tags":["PD-1 • VEGFA • CD34 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 03/02/2028","primary_completion_date":" 03/02/2028","study_txt":" Completion: 08/02/2028","study_completion_date":" 08/02/2028","last_update_posted":"2025-01-30"},{"id":"44b80189-528f-4f15-a751-b2fa0ad145eb","acronym":"PCR-MIB","url":"https://clinicaltrials.gov/study/NCT02662062","created_at":"2025-02-25T18:11:21.641Z","updated_at":"2025-02-25T18:11:21.641Z","phase":"Phase 2","brief_title":"Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02662062 - PCR-MIB","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","biomarkers":" CD20 • CD8 • PD-1 • LAG3 • CD4 • ICOS • FOXP3","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD8 • PD-1 • LAG3 • CD4 • ICOS • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/11/2017","start_date":" 07/11/2017","primary_txt":" Primary completion: 05/12/2022","primary_completion_date":" 05/12/2022","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2025-01-27"},{"id":"65eed3dd-6e61-408e-98c2-7b567021d3e7","acronym":"KEYNOTE-G05","url":"https://clinicaltrials.gov/study/NCT06784648","created_at":"2025-02-25T16:11:37.790Z","updated_at":"2025-02-25T16:11:37.790Z","phase":"Phase 1/2","brief_title":"Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma","source_id_and_acronym":"NCT06784648 - KEYNOTE-G05","lead_sponsor":"BioInvent International AB","biomarkers":" PD-1 • FCGR2A","pipe":"","alterations":" ","tags":["PD-1 • FCGR2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • BI-1607"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 12/11/2024","start_date":" 12/11/2024","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-01-20"}]